Novel effectors of ERK signaling and their potential roles in the treatment of en
ERK 信号传导的新型效应物及其在治疗 en 中的潜在作用
基本信息
- 批准号:7727351
- 负责人:
- 金额:$ 9.34万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-09-18 至 2012-08-12
- 项目状态:已结题
- 来源:
- 关键词:AccountingAntibodiesApoptosisBiological ModelsBiological Response Modifier TherapyCaenorhabditis elegansCancer BiologyCancer Cell GrowthCancer ModelCancer cell lineCell Cycle RegulationCell LineCell ProliferationCell SurvivalCellsClinicalDetectionDiagnosticDiseaseEndometrialEndometrial CarcinomaEndometriumEventFGFR2 geneHemorrhageHumanInstructionKRAS2 geneLeadMalignant Female Reproductive System NeoplasmMalignant NeoplasmsMapsMethodsMitogen-Activated Protein KinasesMitogensModelingMolecular AbnormalityMorbidity - disease rateMutationNeoplasm MetastasisOperative Surgical ProceduresOrthologous GenePathway interactionsPatientsPharmacotherapyPhosphorylationPhosphorylation SitePhosphotransferasesPlayPopulationPostmenopausePreventionProteinsRecurrent Malignant NeoplasmReproduction sporesReverse Transcriptase Polymerase Chain ReactionRoleSignal PathwaySignal TransductionSignal Transduction PathwaySmall Interfering RNAStagingSystemic diseaseTherapeuticTherapeutic InterventionTissue MicroarrayTissuesTumor Suppressor GenesUterine CancerWestern BlottingWorkangiogenesiscarcinogenesiscell growthcell motilitychemotherapyclinically relevantcohorteffective therapyextracellularfunctional genomicsglycogen synthase kinase 3 betaimprovedmortalitymultimodalityneoplasticnovelnovel strategiesnovel therapeutic interventionsmall hairpin RNAtreatment strategytumorigenesis
项目摘要
Endometrial carinoma is the most common cancer of the female reproductive tract. Most endometrial
cancers are found at an early stage and present with postmenopausal bleeding. These patients are initially
treated with comprehensive surgical staging. This treatment is often diagnostic ofthe extent of disease and
therapeutic. However, a key clinical problem in the management of patients with uterine cancers is how to
best fre¿t~ab\r¿rhced'stagieclisease ahdlhe aggressive pathoTogic histotypes that account for signficant
mortality.
Patients with high stage or recurrent cancers have systemic disease requiring novel therapeutic
interventions. Effective therapies are largely lacking. A better understanding ofthe cancer biology, such as
signal transduction pathways, will lead to new treatment strategies that will improve the survival of these
patients. Activation of the Mitogen Activating Pathway Kinase signaling pathway contributes substantially to
endometrial tumorigenesis. Our group has identified thirty novel ERK substrates through a three-part
functional genomic approach in the C. elegans model. The human orthologs of these proteins expressed in
endometrial cancer cell lines are candidate ERK substrates. Thus far, of the candidates studied, we showed
that GSK3n is important to cell growth in multiple endometrial cancer cell lines and has potential for
therapeutic interventions.. In this proposal, we will continue to characterize novel ERK candidate substrates
in endometrial cancer. In Aim 1, we will assess expression of candidate ERK1/2 substrates in the normal
endometrium, primary endometrial cancers and endometrial cancer cell lines and determine if substrate
phosphorylation is ERK-dependent. Then in aim 2, we will determine the relationship between ERK substrate
phosphorylation status and upstream ERK signaling pathway activation in primary endometrial cancers and
clinicopathologic significance of ERK substrate expression. Finally in aim 3, we will explore GSKSD
inhibition as potential therapy for endometrial cancer and assess the role of inhibiting other ERK substrates
plays in endometrial cancer cell lines. Together these studies should provide a better understanding of the
role the ERK pathway plays in endometrial carcinogenesis and may lead to improved clinical biological
therapies.
RELEVANCE (See instructions):
The work proposed will lead to both an improved understanding of endometrial cancer biology and new
approaches to the detection, prevention and treatment of uterine cancers which will result in reduced cancer
morbidity and mortality.
子宫内膜性颈瘤是女性生殖道的最常见癌症。最大的子宫内膜
癌症是在早期发现的,并在绝经后出血。这些患者最初是
通过全面的手术分期治疗。这种治疗通常是诊断疾病程度和
治疗性。但是,子宫癌患者管理中的关键临床问题是如何
最好的自由t〜ab \r¿
死亡。
高阶段或经常性癌症患者患有全身性疾病,需要新的治疗
干预措施。有效的疗法在很大程度上缺乏。更好地了解癌症生物学,例如
信号转导途径将导致新的治疗策略,以改善这些策略
患者。有丝分裂激活途径激活途径激酶信号通路的激活极大地促进
子宫内膜肿瘤发生。我们的小组通过三部分确定了三十个新颖的ERK底物
秀丽隐杆线虫模型中的功能基因组方法。这些蛋白质的人类直系同源物在
子宫内膜癌细胞系是候选ERK底物。在研究候选人的那个远处,我们表明
GSK3N对于多种子宫内膜癌细胞系中的细胞生长很重要,并且有潜力
治疗性干预措施。在此提案中,我们将继续描述新型ERK候选底物
在子宫内膜癌中。在AIM 1中,我们将评估正常情况下候选ERK1/2底物的表达
子宫内膜,原发子宫内膜癌和子宫内膜癌细胞系,并确定底物是否
磷酸化是ERK依赖性的。然后在AIM 2中,我们将确定ERK基板之间的关系
原发子宫内膜癌和上游ERK信号通路的磷酸化状态和上游ERK信号通路激活
ERK底物表达的临床病理学意义。终于在AIM 3中,我们将探索GSKSD
抑制作为子宫内膜癌的潜在疗法和评估抑制其他ERK底物的作用
在子宫内膜癌细胞系中发挥作用。这些研究在一起应该更好地理解
角色ERK途径在子宫内膜致癌中发挥作用,并可能导致临床生物学改善
疗法。
相关性(请参阅说明):
提出的工作将导致对子宫内膜癌生物学和新的新了解
检测,预防和治疗子宫癌的方法,这将导致癌症减少
发病率和死亡率。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Liang Ma其他文献
Liang Ma的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Liang Ma', 18)}}的其他基金
Androgen and Wnt signaling in bladder cancer
膀胱癌中的雄激素和 Wnt 信号传导
- 批准号:
10727745 - 财政年份:2023
- 资助金额:
$ 9.34万 - 项目类别:
GENOME-WIDE IDENTIFICATION OF GENES REQUIRED FOR DECIDUALIZATION
蜕化所需基因的全基因组鉴定
- 批准号:
9258455 - 财政年份:2016
- 资助金额:
$ 9.34万 - 项目类别:
GENERATION OF AN INDUCIBLE SYSTEM IN THE UTERINE STROMA FOR IMPLANTATION STUDIES
用于植入研究的子宫间质中诱导系统的生成
- 批准号:
8358586 - 财政年份:2012
- 资助金额:
$ 9.34万 - 项目类别:
GENERATION OF AN INDUCIBLE SYSTEM IN THE UTERINE STROMA FOR IMPLANTATION STUDIES
用于植入研究的子宫间质中诱导系统的生成
- 批准号:
8522211 - 财政年份:2012
- 资助金额:
$ 9.34万 - 项目类别:
相似国自然基金
分泌IL-6纳米抗体的重组枯草芽孢杆菌通过CXCL10/CXCR3轴介导CD4+效应T细胞凋亡减轻IBD肠道炎症的机制研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
分泌IL-6纳米抗体的重组枯草芽孢杆菌通过CXCL10/CXCR3轴介导CD4+效应T细胞凋亡减轻IBD肠道炎症的机制研究
- 批准号:82200581
- 批准年份:2022
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
抗CD4自身抗体介导CD4+T细胞凋亡在艾滋病免疫无应答患者中的机制及治疗作用
- 批准号:
- 批准年份:2021
- 资助金额:54 万元
- 项目类别:面上项目
抗HuD抗体引起肠易激综合征肠神经元凋亡机制及靶向干预研究
- 批准号:82100568
- 批准年份:2021
- 资助金额:24.00 万元
- 项目类别:青年科学基金项目
抗HuD抗体引起肠易激综合征肠神经元凋亡机制及靶向干预研究
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
The role of osteoblast progenitors in response to bone anabolic agents
成骨细胞祖细胞对骨合成代谢剂的反应的作用
- 批准号:
10404415 - 财政年份:2023
- 资助金额:
$ 9.34万 - 项目类别:
Development of First-in-Class RIPK1 Degraders to Improve Cancer Immunotherapies
开发一流的 RIPK1 降解剂以改善癌症免疫疗法
- 批准号:
10390589 - 财政年份:2022
- 资助金额:
$ 9.34万 - 项目类别:
Development of First-in-Class RIPK1 Degraders to Improve Cancer Immunotherapies
开发一流的 RIPK1 降解剂以改善癌症免疫疗法
- 批准号:
10661495 - 财政年份:2022
- 资助金额:
$ 9.34万 - 项目类别:
Common CD36-dependent gut-brain neuroimmune pathway regulates disruption of intestinal motility in Alzheimer's Disease
常见的 CD36 依赖性肠脑神经免疫途径调节阿尔茨海默氏病肠道运动的破坏
- 批准号:
10448209 - 财政年份:2022
- 资助金额:
$ 9.34万 - 项目类别: